TY  - JOUR
T1  - OPtimal anticoagulation therapy in patients with valvular heart disease or atrial fibrillation—reply
AU  - Torn M, Rosendaal FR
Y1  - 2009/11/23
N1  - 10.1001/archinternmed.2009.421
JO  - Archives of Internal Medicine
SP  - 2033
EP  - 2033
VL  - 169
IS  - 21
N2  - 
With McLeod and Gersh, we believe that, in general, myocardial infarction is not merely an embolic event, but it is thrombotic, and hence “thromboembolic.” Clot formation plays an important role in myocardial infarction, even in severe atherosclerosis. Although not widely used, vitamin K antagonists are effective in preventing myocardial infarction and may well be superior to antiplatelet agents.2 Therefore, we included myocardial infarction as a thromboembolic end point.

SN  - 0003-9926
M3  - doi: 10.1001/archinternmed.2009.421
UR  - http://dx.doi.org/10.1001/archinternmed.2009.421
ER  -